Wells Fargo
UNCY icon

Wells Fargo’s Unicycive Therapeutics UNCY Stock Holding History

Wells Fargo’s Portfolio UNCY Stock Details UNCY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-20
Closed -$270 – 7478
2024
Q1 		$270 Buy
20
+1
+5% +$12 ﹤0.01% 6429
2023
Q4 		$167 Buy
19
+15
+375% +$98 ﹤0.01% 6651
2023
Q3 		$34 Sell
4
-1
-20% -$9 ﹤0.01% 7030
2023
Q2 		$63 Hold
5
– – ﹤0.01% 6991
2023
Q1 		$99 Hold
5
– – ﹤0.01% 6941
2022
Q4 		$25 Hold
5
– – ﹤0.01% 7231
2022
Q3 		$0 Buy
5
+1
+25% +$7 ﹤0.01% 7407
2022
Q2 		$0 Buy
4
+1
+33% +$10 ﹤0.01% 7529
2022
Q1 		$0 Hold
3
– – ﹤0.01% 7849
2021
Q4 		$0 Hold
3
– – ﹤0.01% 7837
2021
Q3 		$0 Buy
+3
New +$86 ﹤0.01% 7547

Other funds holding UNCY

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MIM
Monashee Investment Management Boston, Massachusetts $184M AUM 197.43% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Wells Fargo's UNCY Position: Q2 2024 in Review

Wells Fargo sold out of Unicycive Therapeutics (UNCY) in Q2 2024, closing a stake of 20 shares — an estimated $270 sold.

Wells Fargo first reported a position in UNCY in Q3 2021 and held it in 11 quarters. The position peaked at $270 in Q1 2024. 23 funds tracked by Wall St. Rank hold UNCY as of Q2 2024.

  • Wells Fargo reported no remaining Unicycive Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Wells Fargo sold 20 Unicycive Therapeutics shares in Q2 2024, an estimated $270.
  • Wells Fargo first reported a position in Unicycive Therapeutics in Q3 2021 and held it in 11 quarters.
  • Wells Fargo's Unicycive Therapeutics position peaked at $270 in Q1 2024.
  • 23 funds tracked by Wall St. Rank held Unicycive Therapeutics as of Q2 2024.

Based on Wells Fargo's 13F filing for Q2 2024, filed 13 Aug 2024.